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Meta-Analyses of Statin Trials
Clear Beneﬁt for Primary Prevention
in the Elderly*
David D. Waters, MD
San Francisco, California
Many statin meta-analyses have been published, at least
250 according to my just-completed, informal search of
PubMed. The endpoint of interest for many of these is
incident cancer of a speciﬁc type or site (e.g., melanoma, lung,
bladder, esophagus, liver, breast, or prostate), but many other
diverse conditions have also been reported, including atrial
ﬁbrillation, dementia, osteoporosis, and macular degenera-
tion. The broad scope of these studies is a consequence of the
widespread use of statins and their multiple biologic effects
due to inhibition of the 3-hydroxy-3-methylglutaryl CoA
reductase enzyme. Most of these studies have inherent lim-
itations: they use observational datasets of varying quality
and not clinical trial data, endpoint deﬁnitions are often
not uniform, sample sizes may be too small, and publication
bias may inﬂuence the results.See page 2090The “Rolls Royce” of statin meta-analyses is the Choles-
terol Treatment Trialists’ Collaboration (CTTC). Their
analysis plan was agreed upon before any of the statin trials
were available, and was published in 1995 (1). The Collabo-
ration comprises members of the steering committees of the
trials, and they analyze patient level data. The CTTC estab-
lished that the relationship between low-density lipoprotein
cholesterol (LDL-C) reduction and cardiovascular (CV)
event reduction is approximately linear, with each mmol/l
reduction in LDL-C associated with a 21% reduction in
events (2). The implication of this is that profound LDL-C
reduction will yield profound CV event reduction.
The CTTC analyses conclusively show that the relative
risk reduction from LDL-C lowering with statins is in-
dependent of baseline LDL-C, across the range from
3.5 mmol/l and above down to below 2 mmol/l (3). The
implication of this is that the decision to treat should depend*Editorials published in the Journal of the American College of Cardiology reﬂect the
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recently, the CTTC has reported that relative risk reduction
is independent of the level of baseline risk; although subjects
at higher risk obtain more absolute risk reduction, signiﬁcant
risk reduction still occurs when the 5-year risk of a major
vascular event is 5% to 10%, or even <5% (4).
A clear message from the CTTC reports is that all patient
categories enjoy approximately the same relative CV event
reduction with statins: primary and secondary prevention;
men and women; young and old; and subgroups with dia-
betes, hypertension, current smokers, and different levels of
high-density lipoprotein cholesterol, body mass index, and
renal function (2,3).
Nevertheless, some meta-analyses have focused on
subgroups of clinical interest, usually where risk is low. For
example, in a meta-analysis of 6 trials, including 11,435
women without CV disease published in 2004, no signiﬁ-
cant beneﬁt was seen with statins for any of the CV end-
points (5). The authors did report beneﬁt among women
with established CV disease, and allowed that the lack of
beneﬁt for primary prevention in women may have been
due to the small number of events. Such caution was wise,
because their conclusion was soon reversed. In a meta-
analysis of statins for primary prevention in women pub-
lished 6 years later with larger numbers (6), the relative risk
of CV events for statin-treated women was 0.63 (95%
conﬁdence interval: 0.49 to 0.82; p < 0.001), with a trend
toward a reduction even in total mortality (relative risk: 0.78;
95% conﬁdence interval: 0.53 to 1.15).
When is it essential to have clinical trial data for speciﬁc
subgroups before treating them? In my opinion the answer is
almost never; it is far better to include these subgroups in pivotal
trials from the start. But, one could argue that perhaps women,
diabetics, or Asians are sufﬁciently different in important ways
from the predominantly male, Caucasian population of statin
trials. For the elderly, similar arguments can be made.
At least some evidence suggests that statins might not be
effective in older individuals. With increasing age, total
cholesterol and LDL-C lose their ability to predict CV
events and total mortality (7), and in the very elderly, low
cholesterol levels are associated with an increased mortality
risk (8). In a large observational study of Medicare patients
discharged from the hospital after myocardial infarction
(MI), treatment with a statin was associated with reduced
mortality at 3 years in patients younger than age 80 years,
but not in those age 80 years or older (9).
The consequences of MI and stroke are much more
serious for older than younger patients, both for death and
long-term disability. The incidences of CV events also
increases with increasing age. For these reasons, the elderly
without evidence of atherosclerosis and their caregivers face
a high-stakes decision on statin treatment, with no clear
direction from current guidelines.
The meta-analysis of Savarese et al. (10) in this issue of the
Journal clearly answers the question of whether statins reduce
events in primary prevention of individuals age 65 years
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2101or older. The reduction in the risk for MI was almost 40%
and for stroke was almost one-quarter, albeit with relatively
wide conﬁdence intervals. All-cause and cardiovascular mor-
tality were reduced by 6% and 9% respectively, differences
that were not statistically signiﬁcant.
The discrepancy between the results for MI and stroke on
the one hand, and mortality on the other, is at least partly
a consequence of different trials that were included for
different endpoints. Approximately one-half of the weight
for the mortality outcomes was from the ALLHAT (Anti-
hypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial) trial, where pravastatin did not improve
outcomes, a ﬁnding attributed to the narrow LDL-C
difference between treatment groups (11). The ALLHAT
trial was not included in the analyses for MI or stroke
because those data were unavailable.
On the other hand, of the 5 trials included in the MI
and stroke analyses, and of the 7 included in the mortality
analyses, 3 were stopped early due to beneﬁt. Not surpris-
ingly, these were the trials that used the more potent statins,
atorvastatin and rosuvastatin. Stopping these trials early
limited the contribution that they made to the meta-analysis.
The ﬁndings of the meta-analysis apply to patients similar
to those enrolled in the trials; their mean age was 73 years,
and both women and men were well represented. All had
risk factors in addition to age: hypertension, diabetes, low
high-density lipoprotein cholesterol levels, high LDL-C
levels, or high C-reactive protein levels.
Older people differ more among themselves than younger
people do in many many ways, and the decision to treat or not
treat an older individual with a statin often requires clinical
discernment. The clear results of this meta-analysis will hopefully
lead to more older individuals receiving treatment that will
reduce their CV risk.
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